UNSPSC 51241144: Aflibercept

Aflibercept injection is a prescription medicine administered by injection into the eye. It is a vascular endothelial growth factor (VEGF) inhibitor. https://www.eylea.us/

UNSPSC 51241144 Aflibercept, a Commodity code, shows minimal recent activity aligned with its pharmaceutical scope. The two most recent state and local solicitations posted under this code—one from Texas A&M University requesting precipitant solutions and one from Pasco County, Florida seeking copper sulfate crystals and liquid copper sulfate—are unrelated to aflibercept, a vascular endothelial growth factor inhibitor used in ophthalmologic and oncologic treatment. The mismatch between the code's nominal scope and the actual work being solicited suggests either miscoding of recent opportunities or limited procurement volume under the correct classification.

The code shows no recent activity with clear relevance to state and local purchase of aflibercept itself. Texas A&M University Division of Finance Procurement Services posted ITB TAMU-ITB-26-5055 on June 26, 2026 for precipitant solutions with responses due July 15, 2026, while Pasco County, Florida issued an RFQ on June 3, 2026 for copper sulfate products with a June 26 response deadline. Neither opportunity reflects typical pharmaceutical procurement patterns or the therapeutic indication that would drive aflibercept demand in state and local health systems. Without solicitations that directly name aflibercept or related ophthalmologic or oncologic pharmaceutical supply contracts, the code does not present actionable signal for business development in this commodity category.